Neuroone Medical Technologies is trading at $1.00, up 9.57%, with its first pharmaceutical-industry purchase order for StereoCED the clearest company-specific explanation for the gain.
- Announced October 22, the order supports a preclinical research program; the company, order value and expected revenue were not disclosed.
- The study is expected to begin in large animals early next year. StereoCED is not FDA-cleared or approved.
- Broader markets were lower.